Within the past decade nonvitamin K oral anticoagulants have emerged as the standard of
care for the prevention and treatment of thromboembolic disorders, however safety of
anticoagulants remain a concern for many patients and providers. There exists new interest
in factor XI inhibition as novel therapeutic target based on observations of lower thrombotic
rates and without significant bleed risk in individuals with inherited factor XI deficiency.
Several classes of factor XI inhibitors including antisense oligonucleotides, monoclonal …